187 related articles for article (PubMed ID: 14695041)
1. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Walker PD; Brokering KL; Theobald JC
Pharmacotherapy; 2003 Dec; 23(12):1617-26. PubMed ID: 14695041
[TBL] [Abstract][Full Text] [Related]
2. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
Lepor NE
Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
4. Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis.
Naeem M; McEnteggart GE; Murphy TP; Prince E; Ahn S; Soares G
Clin Imaging; 2015; 39(5):759-64. PubMed ID: 25709111
[TBL] [Abstract][Full Text] [Related]
5. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
[TBL] [Abstract][Full Text] [Related]
6. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
[TBL] [Abstract][Full Text] [Related]
8. Preventing contrast-induced nephropathy with fenoldopam.
Hunter DW; Chamsuddin A; Bjarnason H; Kowalik K
Tech Vasc Interv Radiol; 2001 Mar; 4(1):53-6. PubMed ID: 11981789
[TBL] [Abstract][Full Text] [Related]
9. Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.
van den Berk G; Tonino S; de Fijter C; Smit W; Schultz MJ
Crit Care; 2005 Aug; 9(4):361-70. PubMed ID: 16137385
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery.
Barr LF; Kolodner K
Crit Care Med; 2008 May; 36(5):1427-35. PubMed ID: 18434903
[TBL] [Abstract][Full Text] [Related]
11. The third strike.
Brinker JA
Catheter Cardiovasc Interv; 2002 Nov; 57(3):284-5. PubMed ID: 12410498
[No Abstract] [Full Text] [Related]
12. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit.
Schultz MJ; Baas MC; van der Sluijs HP; Stamkot GA; Smit W
Curr Med Chem; 2006; 13(21):2565-70. PubMed ID: 17017911
[TBL] [Abstract][Full Text] [Related]
14. Acetylcysteine and contrast media nephropathy.
Tepel M; Zidek W
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):503-6. PubMed ID: 12187314
[TBL] [Abstract][Full Text] [Related]
15. Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.
De Shong D; Mathis AS
Pharmacotherapy; 2004 Jun; 24(6):819-20; author reply 820. PubMed ID: 15222676
[No Abstract] [Full Text] [Related]
16. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
Kini AS; Mitre CA; Kim M; Kamran M; Reich D; Sharma SK
Catheter Cardiovasc Interv; 2002 Feb; 55(2):169-73. PubMed ID: 11835641
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG
Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100
[TBL] [Abstract][Full Text] [Related]
18. Prevention of contrast-induced nephropathy in vascular surgery patients.
Lawlor DK; Moist L; DeRose G; Harris KA; Lovell MB; Kribs SW; Elliot J; Forbes TL
Ann Vasc Surg; 2007 Sep; 21(5):593-7. PubMed ID: 17823041
[TBL] [Abstract][Full Text] [Related]
19. Acetylcysteine for radiocontrast nephropathy.
Tepel M; Zidek W
Curr Opin Crit Care; 2001 Dec; 7(6):390-2. PubMed ID: 11805540
[TBL] [Abstract][Full Text] [Related]
20. Does the prophylactic use of N-acetylcysteine prevent contrast nephropathy in patients with renal insufficiency?
Ma IW; Hladunewich M
CMAJ; 2004 Apr; 170(8):1231. PubMed ID: 15078844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
